Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

Diabetes

Volumn 51, Issue 10, 2002, Pages 3090-3094

  Flyvbjerg, Allan ^a   Dagnæs Hansen, Frederlk ^b   De Vriese, An S ^c   Schrijvers, Bieke F ^a,c   Tilton, Ronald G ^d   Rasch, Ruth ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN G; INSULIN; NEUTRALIZING ANTIBODY; PLACEBO; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; KIDNEY MASS; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; THICKNESS; TREATMENT OUTCOME;

EID: 0036789207     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.10.3090     Document Type: Article

References (37)

1. Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223, 2000
2. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, Williamson JR: Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 99:2192-2202, 1997
3. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229-2239, 1999
4. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12:993-1000, 2001
5. Koenig RJ, Cerami A: Synthesis of hemoglobin Alc in normal and diabetic mice: potential model of basement membrane thickening. Proc Natl Acad Sci U S A 72:3687-3691, 1975
6. Gartner K: Glomerular hyperfiltration during onset of diabetes mellitus in two strains of diabetic mice (C57b1/6J db/db and C57b1/ksj db/db). Diabetologia 15:59-63, 1978
7. Bower G, Brown DM, Steffes MW, Vernier RL, Mauer SM: Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse. Lab Invest 43:333-341, 1980
8. Cohen MP, Clements RS, Cohen JA, Shearman CW: Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia 39:270-274, 1996
9. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA: Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48:377-382, 1999
10. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B: The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96:857-881, 1988
11. Pagtalunan ME, Rasch R, Rennke HG, Meyer TW: Morphometric analysis of effects of angiotensin II on glomerular structure in rats. Am J Physiol 268:F82-F88, 1995
12. Weibel ER: Stereologic Methods: Practical Methods for Biological Morphometry. London, Academic Publishers, 1979, p. 51-57
13. Jensen EB, Gundersen HJ, Østerby R: Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 115:19-33, 1979
14. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
15. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312, 1989
16. Tisher E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991
17. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
18. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774-1778, 1990
19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
20. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in humans gliomas in vivo. Nature 359:845-848, 1992
21. Farrara N, Houck KA, Jakeman LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47:211-218, 1991
22. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
23. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253, 1992
24. Brown LF, Berse B, Tognazzi K, Manseau EJ, van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42:1457-1461, 1992
25. Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 268:F240-F250, 1995
26. 125I]VEGF binding sites. J Am Soc Nephrol 9:1044-1044, 1998
27. Williams B: A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy. Miner Electrolyte Metab 24:400-405, 1998
28. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M: Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. JAm Soc Nephrol 10:245-255, 1999
29. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, Viberti G: Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by mesangial cells. J Am Soc Nephrol 10:730-737, 1999
30. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J: Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 42:H2224-H2231, 1997
31. Tsuchida K, Maldta Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T: Suppression of transforming growth factor and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579-588, 1999
32. Duh E, Aiello LP: Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48:1899-1906, 1999
33. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Kumar S: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db mice. Proc Natl Acad Sci U S A 97:8015-8020, 2000
34. Rubin J, Wang H, Tashjian AH Jr, Patterson C: Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262-2268, 1996
35. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor I receptor. Nat Med 5:1390-1395, 1999
36. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46:1473-1480, 1997
37. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43:1360-1367, 2000